Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 29, 2025 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company...
July 28, 2025 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty...
July 21, 2025 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Findings published in the journal of Clinical Genitourinary Cancer show patients remained event-free for a median of two years after achieving complete response with ZUSDURI (mitomycin) intravesical...
July 07, 2025 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
June 17, 2024 16:46 ET | Source: UroGen Pharma Ltd.

UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
August 14, 2018 07:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments

Plan to Initiate Q4 2018 Rolling New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for UGN-101, Ahead of Initial Projection of Q1 2019 Initiated Phase 2b Clinical...
August 08, 2018 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer

Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to Prepare UroGen for its Transition from a Clinical Stage Company to Commercialization...
August 07, 2018 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report second...
July 11, 2018 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel™) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)

Company Expects to Begin U.S. Phase 2b Clinical Trial in Q3 2018 UGN-102 Has Potential to Become the First Front Line Non-Surgical Therapy for Patients with LG NMIBC RA’ANANA, Israel and NEW YORK,...
July 10, 2018 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors

Tomasello is a Renowned Industry Expert Responsible for the Commercialization of Revolutionary, Multi-Billion Dollar Products in Hematology-Oncology RA’ANANA, Israel and NEW YORK, July 10, 2018 ...

Next Page keyboard_arrow_right